Local Treatment of Brain Tumors with Targeted Chimera Cytotoxic Proteins

REFERENCES

• Levin V.A., Sheline G.H., Gutin P.H. Neoplasms of the Central Nervous System. Cancer: Principles and Practice of Oncology. 3rd Ed., J. B. Lippincott Company, Philadelphia 1989; 1557–1611
   Google Scholar
• Kleihues P., Soylemezoglu F., Schauble B., Scheithauer B.W., Burger P.C. Histopathology, Classification, and Grading of Gliomas. Glia 1995; 15: 211–221
   PubMed Web of Science ®Google Scholar
• Davis F.G., Freels S., Grutsch J., Barlas S., Brem S. Survival Rates in Patients with Primary Brain Tumors Stratified by Patient Age and Tumor Histological Type: an Analysis Based on Surveillance, Epidemiology, and End Results (SEER) Data, 1973–1991. J. Neurosurg. 1998; 88: 1–10
   PubMed Web of Science ®Google Scholar
• “Reports from the Front” Science, 267, 1995, 1414.
   Google Scholar
• Olson M.E., Chernik N.L., Posner J.B. Infiltration of the Leptomeninges by Systemic Cancer. Arch. Neurol. 1974; 30: 122–136
   PubMed Web of Science ®Google Scholar
• Brem S., Cotran R., Folkman J. Tumor Angiogenesis: a Quantitative Method for Histologic Grading. J. Natl Cancer Inst. 1972; 48: 347–356
   PubMed Web of Science ®Google Scholar
• Ji Y., Powers S.K., Brown J.T., Miner R. Characterization of the Human Invasion Area in the Rat Intracerebral Glioma. J. Neuro-Oncol. 1996; 30: 189–197
   PubMed Web of Science ®Google Scholar
• Keles G.E., Anderson B., Berger M.S. The Effect of Extent of Resection on Time to Tumor Progression and Survival in Patients with Glioblastoma Multiforme of the Cerebral Hemisphere. Surg. Neurol. 1999; 52: 371–379
   PubMed Web of Science ®Google Scholar
• Leibel S.A., Scott C.B., Loeffler J.S. Contemporary Approaches to the Treatment of Malignant Gliomas with Radiation Therapy. Semin. Oncol. 1994; 21: 198–219
   PubMed Web of Science ®Google Scholar
• Lesser G.J., Grossman S. The Chemotherapy of High-Grade Astrocytomas. Semin. Oncol. 1994; 21: 220–235
   PubMed Web of Science ®Google Scholar
• Herlyn M., Menrad A., Koprowski H. Structure, Function, and Clinical Significance of Human Tumor Antigens. J. Natl Cancer Inst. 1990; 82: 1883–1889
   PubMed Web of Science ®Google Scholar
• Debinski W., Karlsson B., Lindholm L., Siegall C.B., Willingham M.C., FitzGerald D., Pastan I. Monoclonal Antibody C242-Pseudomonas Exotoxin A: A Specific and Potent Immunotoxin with Anti-tumor Activity on a Human Colon Cancer Xenograft in Nude Mice. J. Clin. Investig. 1992; 90: 405–411
   PubMed Web of Science ®Google Scholar
• Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H. Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 1985; 313: 144–147
   PubMed Web of Science ®Google Scholar
• Debinski W., Siegall C.B., FitzGerald D., Pastan I. Substitution of Foreign Protein Sequences into a Chimeric Toxin Composed of Transforming Growth Factor α and Pseudomonas Exotoxin. Mol. Cell. Biol. 1991; 11: 1751–1753
   PubMed Web of Science ®Google Scholar
• Debinski W., Puri R.K., Kreitman R.J., Pastan I. A Wide Range of Human Cancers Express Interleukin 4 (IL4) Receptors that can be Targeted with Chimeric Toxin Composed of IL4 and Pseudomonas Exotoxin. J. Biol. Chem. 1993; 268: 14065–14070
   PubMed Web of Science ®Google Scholar
• Debinski W., Obiri N.I., Pastan I., Puri R.K. A Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4. J. Biol. Chem. 1995; 270: 16775–16780
   PubMed Web of Science ®Google Scholar
• Wikstrand C.J., McLendon R.E., Friedman A.H., Bigner D.D. Cell Surface Localization and Density of the Tumor-Associated Variant of the Epidermal Growth Factor Receptor, EGFRvIII. Cancer Res. 1997; 57: 4130–4140
   PubMed Web of Science ®Google Scholar
• Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., Wong A.J. Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors. Cancer Res. 1995; 55: 5536–5539
   PubMed Web of Science ®Google Scholar
• Kunwar S., Pai L.H., Pastan I. Cytotoxicity and Antitumor Effects of Growth Factor-Toxin Fusion Proteins on Human Glioblastoma Multiforme Cells. J. Neurosurg. 1993; 79: 569–576
   PubMed Web of Science ®Google Scholar
• Martell L.A., Agrawal A., Ross D.A., Muraszko K.M. Efficacy of Transferrin Receptor-Targeted Immunotoxins in Brain Tumor Cell Lines and Pediatric Brain Tumors. Cancer Res. 1993; 53: 1348–1353
   PubMed Web of Science ®Google Scholar
• Morrison R.S., Yamaguchi F., Bruner M.M., Tang M., McKeehan W., Berger M.S. Fibroblast Growth Factor Receptor Gene Expression and Immunoreactivity are Elevated in Human Glioblastoma Multiforme. Cancer Res. 1994; 54: 2794–2799
   PubMed Web of Science ®Google Scholar
• Tureci O., Sahin U., Zwick C., Neumann F., Pfreundschuh M. Exploitation of the Antibody Repertoire of Cancer Patients for the Identification of Human Tumor Antigens. Hybridoma 1999; 18: 23–28
   PubMed Web of Science ®Google Scholar
• Debinski W., Gibo D.M. Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-Associated Cancer/Testis Antigen. Mol. Med. 2000; 6: 440–449
   PubMed Web of Science ®Google Scholar
• Moolten F.L., Cooperband S.R. Selective Destruction of Target Cells by Diphtheria Toxin Conjugated to Antibody Directed Against Antigen on the Cells. Science 1970; 169(July)68–70
   PubMedGoogle Scholar
• Pastan I., Chaudhary V.K., Fitzgerald D. Recombinant Toxins as Novel Therapeutic Agents. Annu. Rev. Biochem. 1992; 61: 331–354
   PubMed Web of Science ®Google Scholar
• Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of Advanced Solid Tumors With Immunotoxin LMB-1: An Antibody Linked to Pseudomonas Exotoxin. Nature Med. 1996; 2: 350–353
   PubMed Web of Science ®Google Scholar
• Laske D.W., Youle R.J., Oldfield E.H. Tumor Regression with Regional Distribution of the Targeted Toxin TF-CRM107 in Patients with Malignant Brain Tumors. Nature Med. 1997; 3: 1362–1368
   PubMed Web of Science ®Google Scholar
• Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/Function Analysis of Interleukin-2-Toxin (DAB486-IL-2). J. Biol. Chem. 1990; 265: 11885–11889
   PubMed Web of Science ®Google Scholar
• Caraglia M., Budillon A., Vitale G., Lupoli G., Tagliaferri P., Abbruzzese A. Modulation of Molecular Mechanisms Involved in Protein Synthesis Machinery as a New Tool for the Control of Cell Proliferation. Eur. J. Biochem. 2000; 267: 3919–3936
   PubMedGoogle Scholar
• Laske D.W., Ilercil O., Akbasak A., Youle R.J., Oldfield E.H. Efficacy of Direct Intratumoral Therapy with Targeted Protein Toxins for Solid Human Gliomas in Nude Mice. J. Neurosurg. 1994; 80: 520–526
   PubMed Web of Science ®Google Scholar
• Recht L.D., Griffin T.W., Raso V., Salimi A.R. Potent Cytotoxicity of an Antihuman Transferrin Receptor-Ricin A-Chain Immunotoxin on Human Glioma Cells In Vitro. Cancer Res. 1990; 50: 6696–6700
   PubMed Web of Science ®Google Scholar
• Debinski W., Obiri N.I., Powers S.K., Pastan I., Puri R.K. Human Glioma Cells Over-Express Receptor for Interleukin 13 and Are Extremely Sensitive to a Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin. Clin. Cancer Res. 1995; 1: 1253–1258
   PubMed Web of Science ®Google Scholar
• Vitetta E.S., Fulton R.J., May R.D., Till M., Uhr J.W. Redesigning Nature's Poison to Create Anti-tumor Reagents. Science 1987; 238: 1098–1104
   PubMed Web of Science ®Google Scholar
• Youle R.J., Neville D.M. Anti-thy 1.2 Monoclonal Antibody Linked to Ricin is a Potent Cell-Type-Specific Toxin. Proc. Natl Acad. Sci. USA 1980; 77: 5483–5486
   PubMed Web of Science ®Google Scholar
• Ross B.D., Kim B., Davidson B.L. Assessment of Ganciclovir Toxicity to Experimental Intracranial Gliomas Following Recombinant Adenoviral-Mediated Transfer of the Herpes Simlex Virus Thymidine Kinase Gene by Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy. Clin. Cancer Res. 1995; 1: 651–657
   PubMed Web of Science ®Google Scholar
• Ram Z., Culver K.W., Oshiro E.M., Viola J.J., DeVroom H.L., Otto E., Long Z., Chiang Y., McGarrity G.J., Muul L.M., Katz D., Blaese R.M., Oldfield E.H. Therapy of Malignant Brain Tumors by Intratumoral Implantation of Retroviral Vector-Producing Cells. Nature Med. 1997; 3: 1354–1361
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C., Fueyo J., Kyritsis A.P., Steck P.A., Roth J.A., McDonnell T.J., Steck K.D., Levin V.A., Yung W.K.A. Adenovirus-Mediated Transfer of the P53 Gene Produces Rapid and Generalized Death of Human Glioma Cells via Apoptosis. Cancer Res. 1996; 56: 694–699, Advances in Brief
   PubMed Web of Science ®Google Scholar
• Debinski W., Miner R., Obiri N.I., Puri R.K. Receptor for IL 13 does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on human Glioma Cells. J. Biol. Chem. 1996; 271: 22428–22433
   PubMed Web of Science ®Google Scholar
• Keppler-Hafkemeyer A., Brinkmann U., Pastan I. Role of Caspases in Immunotoxin-Induced Apoptosis of Cancer Cells. Biochemistry 1998; 37(48)16934–16942
   PubMed Web of Science ®Google Scholar
• Keppler-Hafkemeyer A., Kreitman R.J., Pastan I. Apoptosis Induced by Immunotoxins used in the Treatment of Hematologic Malignancies. Int. J. Cancer 2000; 87: 86–94
   PubMed Web of Science ®Google Scholar
• Debinski W., Pastan I. Recombinant F(ab) C242-Pseudomonas Exotoxin, But Not the Whole Antibody-Based Immunotoxin, Causes Regression of a Human Colorectal Tumor Xenograft. Clin. Cancer Res. 1995; 1: 1015–1022
   PubMed Web of Science ®Google Scholar
• Debinski W., Pastan I. Monovalent Immunotoxin Containing Truncated Form of Pseudomonas Exotoxin as Potent Antitumor Agent. Cancer Res. 1992; 52: 5379–5385
   PubMed Web of Science ®Google Scholar
• Reiter Y., Pastan I. Recombinant Fv Immunotoxins and Fv Fragments as Novel Agents for Cancer Therapy and Diagnosis. Trends Biotechnol. 1998; 16: 513–520
   PubMed Web of Science ®Google Scholar
• Iglewski B.H., Kabat D. NAD-Dependent Inhibition of Protein Synthesis by Pseudomonas aeruginosa Toxin. Proc. Natl Acad. Sci., USA 1975; 72: 2284–2288
   PubMed Web of Science ®Google Scholar
• Introduction to the Blood–Brain Barrier: Methodology, Biology and Pathology, William M. Pardridge. Cambridge University Press, Cambridge, England 1998
   Google Scholar
• Huwyler J., Dafang W., Pardridge W.M. Brain Drug Delivery of Small Molecules Using Immunoliposomes. Proc. Natl Acad. Sci. USA 1996; 93: 14164–14169
   PubMed Web of Science ®Google Scholar
• Long D.M. Capillary Ultrastructure and the Blood–Brain Barrier in Human Malignant Brain Tumors. J. Neurosurg. 1970; 32: 127–144
   PubMed Web of Science ®Google Scholar
• Wersall P., Ohlsson I., Biberfeld P., Collins V., von Krusenstjerna, Larsson S., Mellstebt H., Boethims J. Intratumoral Infusion of the Monoclonal Antibody, mAb 425, Against the Epidermal-Growth-Factor Receptor in Patients with Advanced Malignant Glioma. Cancer Immunol. Immunother. 1997; 44: 157–164
   PubMed Web of Science ®Google Scholar
• Griffon-Etienne G., Boucher Y., Jain R.K., Suite H.D. Effects of Needle Insertion in Tumors on Interstitial Fluid Pressure. Microvasc. Res. 1997; 54: 174–177
   PubMed Web of Science ®Google Scholar
• Baluna R., Rizo J., Gordon B.E., Ghetie V., Vitetta E.S. Evidence for a Structural Motif in Toxins and Interleukin-2 that May Be Responsible for Binding to Endothelial Cells and Initiating Vascular Leak Syndrome. Proc. Natl Acad. Sci. USA 1999; 96: 3957–3962
   PubMed Web of Science ®Google Scholar
• Connor J.R., Fine R.E. The Distribution of Transferrin Immunoreactivity in the Rat Central Nervous System. Brain Res. 1986; 368: 319–328
   PubMed Web of Science ®Google Scholar
• Hill J.M., Ruff M.R., Weber R.J., Pert C.B. Transferrin Receptor in Rat Brain: Neuropeptide-Like Pattern and Relationship to Iron Distribution. Proc. Natl Acad. Sci. USA 1985; 82: 4553–4557
   PubMed Web of Science ®Google Scholar
• Debinski W., Slagle B., Gibo D.M., Powers S.K., Gillespie G.Y. Expression of a Restrictive Receptor for Interleukin 13 Is Associated with Glial Transformation. J. Neuro-Oncol. 2000; 48: 103–111
   PubMed Web of Science ®Google Scholar
• Zovickian J., Johnson V.G., Youle R.J. Potent and Specific Killing of Human Maligant Brain Tumor Cells by an Anti-transferrin Receptor Antibody-Ricin Immunotoxin. J. Neurosurg. 1987; 66: 850–861
   PubMed Web of Science ®Google Scholar
• Recht L., Torres C.O., Smith T.W., Raso V., Griffin T.W. Transferrin Receptor in Normal and Neoplastic Brain Tissue: Implications for Brain-Tumor Immunotherapy. J. Neurosurg. 1990; 72: 941–945
   PubMed Web of Science ®Google Scholar
• Martell L.A., Agrawal A., Ross D.A., Muraszko K.M. Efficacy of Transferrin Receptor-Targeted Immunotoxins in Brain Tumor Cell Lines and Pediatric Brain Tumors. Cancer Res. 1993; 53: 1348–1353
   PubMed Web of Science ®Google Scholar
• Oldfield, E.H. Convection-Enhanced Delivery Brain Tumor Therapy: Advantages and Disadvantages. 14th International Conference on Brain Tumor Research and Therapy, Asheville, NC, May 2001.
   Google Scholar
• Debinski W., Miner R., Gibo D., Puri R.K. Novel Way to Increase Targeting Specificity to a Human Glioblastoma-Associated Receptor for Interleukin 13. Int. J. Cancer 1998; 76: 547–551
   PubMed Web of Science ®Google Scholar
• Humphrey P.A., Wong A.J., Vogelstein B., Friedman H.S., Werner M.H., Bigner D.D., Bigner S.H. Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Res. 1988; 48: 2231–2238
   PubMed Web of Science ®Google Scholar
• Wikstrand C.J., Hale L.P., Batra S.K., Hill L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J., Traweek T., Wong A.J., Zalutsky M.R., Bigner D.D. Monoclonal Antibodies Against EGFRvIII are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. Cancer Res. 1995; 55: 3140–3148
   PubMed Web of Science ®Google Scholar
• Lorimer I.A., Wikstrand C.J., Batra S.K., Bigner D.D., Pastan I. Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors. Clin. Cancer Res. 1995; 1: 859–864
   PubMed Web of Science ®Google Scholar
• Minty A., Chalon P., Derocq J.M., Dumont X., Guillemot J.C., Kaghad M., Labit C., Leplatois P., Liauzun P., Miloux B., Minty C., Casellas P., Loison G., Lupker J., Shire D., Ferrara P., Caput D. Interleukin-13 is a New Human Lymphokine Regulating Inflammatory and Immune Responses. Nature 1993; 362: 248–251
   PubMed Web of Science ®Google Scholar
• McKenzie A.N.J., Culpepper J.A., De Waal Malefyt R., Briere F., Punnonen J., Aversa G., Sato A., Dang W., Cocks B.G., Menon S., De Vries J.E., Banchereau J., Zurawski G. Interleukin 13, a T-Cell-Derived Cytokine that Regulates Human Monocyte and B-Cell Function. Proc. Natl Acad. Sci. USA. 1993; 90: 3735–3739
   PubMed Web of Science ®Google Scholar
• Debinski W., Pastan I. An Immunotoxin with Increased Activity and Homogeneity Produced by Reducing the Number of Lysine Residues in Recombinant Pseudomonas Exotoxin. Bioconjug. Chem. 1994; 5: 40–46
   PubMed Web of Science ®Google Scholar
• Debinski W. An Immune Regulatory Cytokine Receptor and Glioblastoma Multiforme: An Unexpected Link. Crit. Rev. Oncogen. 1998; 9: 255–268
   PubMed Web of Science ®Google Scholar
• Debinski W., Gibo D.M., Kealiher A., Puri R.K. Novel Anti-brain Tumor Cytotoxins Specific for Cancer Cells. Nature Biotechnol. 1998; 16: 449–453
   PubMed Web of Science ®Google Scholar
• Debinski W., Gibo D.M., Hulet S.W., Connor J.R., Gillespie G.Y. Receptor for Interleukin 13 is a Marker and Therapeutic Target for Human High-Grade Gliomas. Clin. Cancer Res. 1999; 5: 985–990
   PubMed Web of Science ®Google Scholar
• Debinski W., Gibo D.M., Slagle B., Powers S.K., Gillespie G.Y. Receptor for Interleukin 13 is Abundantly and Specifically Over-expressed in Patients with Glioblastoma Multiforme. Int. J. Oncol. 1999; 15: 481–486
   PubMed Web of Science ®Google Scholar
• Debinski W., Nash K.T., Thompson J.P. Rationally Designed Multiply Mutated Interleukin 13-Based Cytotoxins for the Treatment of Gliomas. Neuro-Oncology 2000; 2: 259
   Google Scholar
• Mintz A., Debinski W. Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies. Crit. Rev. Oncogen. 2000; 11: 77–95
   PubMed Web of Science ®Google Scholar
• Caput D., Laurent P., Kaghad M., Lelias J.-M., Lefort S., Vita N., Ferrara P. Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain. J. Biol. Chem. 1996; 271: 16921–16926
   PubMed Web of Science ®Google Scholar
• Hilton D.J., Zhang J.-G., Metcalf D., Alexander W.S., Nicola N.A., Wilson T.A. Cloning and Characterization of a Binding Subunit of the Interleukin 13 Receptor That is Also a Component of the Interleukin 4 Receptor. Proc. Natl Acad. Sci. USA 1996; 93: 497–501
   PubMed Web of Science ®Google Scholar
• Zurawski S.M., Vega F., Jr., Huyghe B., Zurawski G. Receptors for Interleukin-13 and Interleukin-4 Are Complex and Share a Novel Component That Functions in Signal Transduction. EMBO J. 1993; 12: 2663–2670
   PubMed Web of Science ®Google Scholar
• Guo J., Apiou F., Mellerin M.-P., Lebeau B., Jacques Y., Minvielle S. Chromosome Mapping and Expression of the Human Interleukin-13 Receptor. Genomics 1997; 42: 141–145
   PubMed Web of Science ®Google Scholar
• Donaldson D.D., Whitters M.J., Fitz L.J., Neben T.Y., Finnerty H., Henderson S.L., O'Hrajr R.M., Beier D.R., Turner K.J., Wood C.R., Collins M. The Murine IL-13 Receptor Alpha 2: Molecular Cloning, Characterization and Comparison with Murine IL-13 Receptor Alpha 1. J. Immunol. 1998; 161: 2317–2324
   PubMed Web of Science ®Google Scholar
• Walter K.A., Cahan M.A., Gur A., Tyler B., Hilton J., Colvin O.M., Burger P.C., Domb A., Brem H. Interstitial Taxol Delivered from a Biodegradable Polymer Implant Against Experimental Malignant Glioma. Cancer Res. 1994; 54: 2207–2212
   PubMed Web of Science ®Google Scholar